1. Marc TG, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute. Bethesda, MD: NIH Pub.; 1999. pp. 65-72.

2. Gurney JG, Smith MA, Ross JA. Cancer among infants. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute. Bethesda, MD: NIH Pub.; 1999. pp. 149-56.

3. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol 2013;35:337-47.

4. American-Cancer-Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2013. pp. 1-64.

5. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010;28:2625-34.

6. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592-601.

7. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009;45:2835-42.

8. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011;29:3286-92.

9. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.

10. Grau E, Oltra S, Orellana C, Hernandez-Marti M, Castel V, et al. There is no evidence that the SDHB gene is involved in neuroblastoma development. Oncol Res 2005;15:393-8.

11. Castel V, Villamon E, Canete A, Navarro S, Ruiz A, et al. Neuroblastoma in adolescents: genetic and clinical characterisation. Clin Transl Oncol 2010;12:49-54.

12. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009;9:729-37.

13. Jrebi NY, Iqbal CW, Joliat GR, Sebo TJ, Farley DR. Review of our experience with neuroblastoma and ganglioneuroblastoma in adults. World J Surg 2014;38:2871-4.

14. Magro G, Grasso S. The glial cell in the ontogenesis of the human peripheral sympathetic nervous system and in neuroblastoma. Pathologica 2001;93:505-16.

15. Crane JF, Trainor PA. Neural crest stem and progenitor cells. Annu Rev Cell Dev Biol 2006;22:267-86.

16. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838-45.

17. Schwab M, Evans A. Neuroblastoma - developmental and molecular biology meet therapy design. Cancer Lett 2003;197:1.

18. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.

19. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397-411.

20. Saad DF, Gow KW, Milas Z, Wulkan ML. Laparoscopic adrenalectomy for neuroblastoma in children: a report of 6 cases. J Pediatr Surg 2005;40:1948-50.

21. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer 2008;112:2796-801.

22. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011;56:578-83.

23. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008;68:2599-609.

24. Barbieri E, De Preter K, Capasso M, Chen Z, Hsu DM, et al. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res 2014;74:765-74.

25. Schleiermacher G, Janoueix-Lerosey I, Delattre O. Recent insights into the biology of neuroblastoma. Int J Cancer 2014;135:2249-61.

26. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.

27. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-9.

28. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, et al. MicroRNA expression in zebrafish embryonic development. Science 2005;309:310-1.

29. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55.

30. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.

31. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.

32. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228-33.

33. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5.

34. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006;26:8191-201.

35. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.

36. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007;282:2135-43.

37. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007;109:4399-405.

38. Murray MJ, Bell E, Raby KL, Rijlaarsdam MA, Gillis AJ, et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br J Cancer 2016;114:151-62.

39. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010;11:537-61.

40. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010;299:L861-71.

41. Frankel LB, Lund AH. MicroRNA regulation of autophagy. Carcinogenesis 2012;33:2018-25.

42. Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther 2012;19:723-30.

43. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67:1419-23.

44. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007;282:1479-86.

45. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004;101:11755-60.

46. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.

47. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54.

48. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.

49. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.

50. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 2008;105:1608-13.

51. Khraiwesh B, Arif MA, Seumel GI, Ossowski S, Weigel D, et al. Transcriptional control of gene expression by microRNAs. Cell 2010;140:111-22.

52. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4.

53. Ward NJ, Green D, Higgins J, Dalmay T, Munsterberg A, et al. MicroRNAs associated with early neural crest development in Xenopus laevis. BMC Genomics 2018;19:59.

54. Weiner AMJ. MicroRNAs and the neural crest: from induction to differentiation. Mech Dev 2018;154:98-106.

55. Sheehy NT, Cordes KR, White MP, Ivey KN, Srivastava D. The neural crest-enriched microRNA miR-452 regulates epithelial-mesenchymal signaling in the first pharyngeal arch. Development 2010;137:4307-16.

56. Beckers A, Van Peer G, Carter DR, Mets E, Althoff K, et al. MYCN-targeting miRNAs are predominantly downregulated during MYCNdriven neuroblastoma tumor formation. Oncotarget 2015;6:5204-16.

57. Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, et al. Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN. Cancer Res 2018;78:3122-34.

58. Zhao Z, Ma X, Hsiao TH, Lin G, Kosti A, et al. A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. Oncotarget 2014;5:2499-512.

59. Zhao Z, Ma X, Sung D, Li M, Kosti A, et al. MicroRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol 2015;12:538-54.

60. Zhao Z, Ma X, Shelton SD, Sung DC, Li M, et al. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. Oncotarget 2016;7:79372-87.

61. Zhao Z, Partridge V, Sousares M, Shelton SD, Holland CL, et al. MicroRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. PLoS One 2018;13:e0208777.

62. Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009;15:456-62.

63. Schulte JH, Horn S, Schlierf S, Schramm A, Heukamp LC, et al. MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett 2009;274:10-5.

64. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.

65. Tonini GP, Romani M. Genetic and epigenetic alterations in neuroblastoma. Cancer Lett 2003;197:69-73.

66. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976-83.

67. Buechner J, Einvik C. N-myc and noncoding RNAs in neuroblastoma. Mol Cancer Res 2012;10:1243-53.

68. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009;4:e7850.

69. Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, et al. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene 2013;32:2927-36.

70. Romania P, Bertaina A, Bracaglia G, Locatelli F, Fruci D, et al. Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives. Int J Mol Sci 2012;13:16554-79.

71. Parodi F, Carosio R, Ragusa M, Di Pietro C, Maugeri M, et al. Epigenetic dysregulation in neuroblastoma: a tale of miRNAs and DNA methylation. Biochim Biophys Acta 2016;1859:1502-14.

72. He XY, Tan ZL, Mou Q, Liu FJ, Liu S, et al. MicroRNA-221 enhances MYCN via targeting nemo-like kinase and functions as an oncogene related to poor prognosis in neuroblastoma. Clin Cancer Res 2017;23:2905-18.

73. Zhao D, Tian Y, Li P, Wang L, Xiao A, et al. MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68. Mol Med Rep 2015;12:5554-60.

74. Xiang X, Mei H, Zhao X, Pu J, Li D, et al. miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14. Oncotarget 2015;6:22452-66.

75. Xiang X, Mei H, Qu H, Zhao X, Li D, et al. miRNA-584-5p exerts tumor suppressive functions in human neuroblastoma through repressing transcription of matrix metalloproteinase 14. Biochim Biophys Acta 2015;1852:1743-54.

76. Meng H, Huang Q, Zhang X, Huang J, Shen R, et al. MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10. Onco Targets Ther 2019;12:3829-38.

77. Cheng J, Wu LM, Deng XS, Wu J, Lv Z, et al. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway. Hepatobiliary Pancreat Dis Int 2018;17:336-44.

78. Li F, Liang J, Bai L. MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression. Biomed Pharmacother 2018;103:782-9.

79. Xu B, Zhang X, Wang S, Shi B. MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer. Pathol Res Pract 2018;214:790-5.

80. Li Y, Jiang T, Shao L, Liu Y, Zheng C, et al. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma. J Neurooncol 2016;129:423-31.

81. Mao A, Liu Y, Wang Y, Zhao Q, Zhou X, et al. miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells. Tumour Biol 2016;37:4831-40.

82. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008;6:14.

83. Ko HY, Lee J, Lee YS, Choi Y, Ali BA, et al. Bioimaging of transcriptional activity of microRNA124a during neurogenesis. Biotechnol Lett 2015;37:2333-40.

84. Choi KH, Shin CH, Lee WJ, Ji H, Kim HH. Dual-strand tumor suppressor miR-193b-3p and -5p inhibit malignant phenotypes of lung cancer by suppressing their common targets. Biosci Rep 2019;39:BSR20190634.

85. Hashemi ZS, Forouzandeh Moghadam M, Khalili S, Ghavami M, Salimi F, et al. Additive effect of metastamiR-193b and breast cancer metastasis suppressor 1 as an anti-metastatic strategy. Breast Cancer 2019;26:215-28.

86. Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, et al. Endogenous tumor suppressor microRNA-193b: therapeutic and prognostic value in acute myeloid leukemia. J Clin Oncol 2018;36:1007-16.

87. Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, et al. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene 2015;34:5923-32.

88. Chen J, Zhang X, Lentz C, Abi-Daoud M, Pare GC, et al. miR-193b regulates Mcl-1 in melanoma. Am J Pathol 2011;179:2162-8.

89. Roth SA, Hald OH, Fuchs S, Lokke C, Mikkola I, et al. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN. Oncotarget 2018;9:18160-79.

90. Zhang H, Pu J, Qi T, Qi M, Yang C, et al. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 2014;33:387-97.

91. Ye D, Zhou C, Deng H, Lin L, Zhou S. MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway. Cancer Manag Res 2019;11:3801-12.

92. Zhang XF, Zhang XQ, Chang ZX, Wu CC, Guo H. MicroRNA145 modulates migration and invasion of bladder cancer cells by targeting Ncadherin. Mol Med Rep 2018;17:8450-6.

93. Lin Y, Ge X, Wen Y, Shi ZM, Chen QD, et al. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget 2016;7:70857-68.

94. Chen Y, Sun Y, Rao Q, Xu H, Li L, et al. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget 2015;6:31203-15.

95. Noguchi S, Mori T, Hoshino Y, Yamada N, Nakagawa T, et al. Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci 2012;74:1-8.

96. Chen Z, Zeng H, Guo Y, Liu P, Pan H, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010;29:151.

97. Wan X, Cheng Q, Peng R, Ma Z, Chen Z, et al. ROCK1, a novel target of miR-145, promotes glioma cell invasion. Mol Med Rep 2014;9:1877-82.

98. Lee JJ, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012;31:3818-25.

99. Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer 2015;136:1308-20.

100. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008;27:5204-13.

101. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010;9:83.

102. Stallings RL, Foley NH, Bryan K, Buckley PG, Bray I. Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets 2010;14:951-62.

103. Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, et al. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 2011;11:33.

104. Chen Y, Tsai YH, Tseng SH. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Surgery 2013;153:4-16.

105. Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, et al. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS One 2011;6:e28356.

106. Lynch J, Fay J, Meehan M, Bryan K, Watters KM, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 2012;33:976-85.

107. Zhang H, Qi M, Li S, Qi T, Mei H, et al. MicroRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 2012;11:1454-66.

108. Chio CC, Lin JW, Cheng HA, Chiu WT, Wang YH, et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol 2013;87:459-68.

109. Li Y, Wang H, Li J, Yue W. MiR-181c modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7. Acta Biochim Biophys Sin (Shanghai) 2014;46:48-55.

110. Maugeri M, Barbagallo D, Barbagallo C, Banelli B, Di Mauro S, et al. Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma. Oncotarget 2016;7:83330-41.

111. Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013;41:6018-33.

112. Lodrini M, Poschmann G, Schmidt V, Wunschel J, Dreidax D, et al. Minichromosome maintenance complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells. J Proteome Res 2016;15:2178-86.

113. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011;469:216-20.

114. Saeki N, Saito A, Sugaya Y, Amemiya M, Sasaki H. Indirect down-regulation of tumor-suppressive let-7 family microRNAs by LMO1 in neuroblastoma. Cancer Genomics Proteomics 2018;15:413-20.

115. Powers JT, Tsanov KM, Pearson DS, Roels F, Spina CS, et al. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature 2016;535:246-51.

116. Soriano A, Masanas M, Boloix A, Masia N, Paris-Coderch L, et al. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma. Cell Mol Life Sci 2019;76:2231-43.

117. Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, et al. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. Cancer Lett 2015;366:123-32.

118. Chen X, Pan M, Han L, Lu H, Hao X, et al. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett 2013;587:3729-37.

119. Raghunath M, Patti R, Bannerman P, Lee CM, Baker S, et al. A novel kinase, AATYK induces and promotes neuronal differentiation in a human neuroblastoma (SH-SY5Y) cell line. Brain Res Mol Brain Res 2000;77:151-62.

120. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902-10.

121. Wu T, Lin Y, Xie Z. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma. Biol Res 2018;51:13.

122. Li SH, Li JP, Chen L, Liu JL. miR-146a induces apoptosis in neuroblastoma cells by targeting BCL11A. Med Hypotheses 2018;117:21-7.

123. Feinberg-Gorenshtein G, Guedj A, Shichrur K, Jeison M, Luria D, et al. MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma. PLoS One 2013;8:e78713.

124. Qu H, Zheng L, Pu J, Mei H, Xiang X, et al. miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Hum Mol Genet 2015;24:2539-51.

125. Qu H, Zheng L, Song H, Jiao W, Li D, et al. MicroRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5’-untranslated region in neuroblastoma. Oncotarget 2016;7:40657-73.

126. Liu G, Xu Z, Hao D. MicroRNA451 inhibits neuroblastoma proliferation, invasion and migration by targeting macrophage migration inhibitory factor. Mol Med Rep 2016;13:2253-60.

127. Li Z, Xu Z, Xie Q, Gao W, Xie J, et al. miR-1303 promotes the proliferation of neuroblastoma cell SH-SY5Y by targeting GSK3beta and SFRP1. Biomed Pharmacother 2016;83:508-13.

128. Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, et al. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 2013;73:4134-46.

129. Liu X, Peng H, Liao W, Luo A, Cai M, et al. MiR-181a/b induce the growth, invasion, and metastasis of neuroblastoma cells through targeting ABI1. Mol Carcinog 2018;57:1237-50.

130. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 2010;16:1134-40.

131. De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011;17:7684-92.

132. Chen Y, Tsai YH, Fang Y, Tseng SH. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg 2012;47:1797-805.

133. Buechner J, Henriksen JR, Haug BH, Tomte E, Flaegstad T, et al. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Differentiation 2011;81:25-34.

134. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008;3:e2236.

135. Buhagiar A, Ayers D. Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma. Anal Cell Pathol (Amst) 2015;2015:150634.

136. Ribeiro D, Klarqvist MDR, Westermark UK, Oliynyk G, Dzieran J, et al. Regulation of nuclear hormone receptors by MYCN-driven miRNAs impacts neural differentiation and survival in neuroblastoma patients. Cell Rep 2016;16:979-93.

137. Takwi AA, Wang YM, Wu J, Michaelis M, Cinatl J, et al. miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene 2014;33:3717-29.

138. Sun F, Fu H, Liu Q, Tie Y, Zhu J, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008;582:1564-8.

139. Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 2012;7:e38129.

140. Marengo B, Monti P, Miele M, Menichini P, Ottaggio L, et al. Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Sci Rep 2018;8:13762.

141. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 2012;107:967-76.

142. Arevalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 2006;63:1523-37.

143. Sun YX, Yang J, Wang PY, Li YJ, Xie SY, et al. Cisplatin regulates SH-SY5Y cell growth through downregulation of BDNF via miR-16. Oncol Rep 2013;30:2343-9.

144. Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, et al. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 2013;12:23.

145. Bhavsar SP, Lokke C, Flaegstad T, Einvik C. Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells. Oncol Lett 2018;16:6786-94.

146. Ayers D, Mestdagh P, Van Maerken T, Vandesompele J. Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015;13:307-19.

147. Zhi F, Wang R, Wang Q, Xue L, Deng D, et al. MicroRNAs in neuroblastoma: small-sized players with a large impact. Neurochem Res 2014;39:613-23.

148. Tivnan A, Foley NH, Tracey L, Davidoff AM, Stallings RL. MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res 2010;30:4391-5.

149. Chakrabarti M, Khandkar M, Banik NL, Ray SK. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res 2012;1454:1-13.

150. Harvey H, Piskareva O, Creevey L, Alcock LC, Buckley PG, et al. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer 2015;136:1579-88.

151. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst 2015;107:djv135.

152. Haug BH, Hald OH, Utnes P, Roth SA, Lokke C, et al. Exosome-like extracellular vesicles from MYCN-amplified neuroblastoma cells contain oncogenic miRNAs. Anticancer Res 2015;35:2521-30.

153. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910.

154. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6.

155. Truckenmiller ME, Vawter MP, Cheadle C, Coggiano M, Donovan DM, et al. Gene expression profile in early stage of retinoic acid-induced differentiation of human SH-SY5Y neuroblastoma cells. Restor Neurol Neurosci 2001;18:67-80.

156. Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, et al. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A 2007;104:7957-62.

157. Meseguer S, Mudduluru G, Escamilla JM, Allgayer H, Barettino D. MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). J Biol Chem 2011;286:4150-64.

158. Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, et al. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 2009;23:4276-87.

159. Guidi M, Muinos-Gimeno M, Kagerbauer B, Marti E, Estivill X, et al. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Mol Biol 2010;11:95.

160. Roth SA, Knutsen E, Fiskaa T, Utnes P, Bhavsar S, et al. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment. Cancer Lett 2016;372:128-36.

161. Nallasamy P, Chava S, Verma SS, Mishra S, Gorantla S, et al. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: immuno-oncology perspective. Semin Cancer Biol 2018;52:53-65.

162. Verissimo CS, Molenaar JJ, Fitzsimons CP, Vreugdenhil E. Neuroblastoma therapy: what is in the pipeline? Endocr Relat Cancer 2011;18:R213-31.

163. Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L, et al. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted oncolytic semliki forest virus. Clin Cancer Res 2017;23:1519-30.

164. Du X, Wang H, Xu F, Huang Y, Liu Z, et al. Enterovirus 71 induces apoptosis of SHSY5Y human neuroblastoma cells through stimulation of endogenous microRNA let-7b expression. Mol Med Rep 2015;12:953-9.

165. Mundalil Vasu M, Anitha A, Takahashi T, Thanseem I, Iwata K, et al. Fluoxetine increases the expression of miR-572 and miR-663a in human neuroblastoma cell lines. PLoS One 2016;11:e0164425.

166. Sousares M, Partridge V, Weigum S, Du L. MicroRNAs in neuroblastoma differentiation and differentiation therapy. Adv Mod Oncol Res 2017;3:213-22.

167. Curtin C, Nolan JC, Conlon R, Deneweth L, Gallagher C, et al. A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models. Acta Biomater 2018;70:84-97.

168. Wang X, Li J, Xu X, Zheng J, Li Q. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10. Biomed Pharmacother 2018;103:1312-8.

169. Ramaiah MJ, Pushpavalli SN, Lavanya A, Bhadra K, Haritha V, et al. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis. Bioorg Med Chem Lett 2013;23:5699-706.

170. Ren X, Bai X, Zhang X, Li Z, Tang L, et al. Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells. Mol Cell Proteomics 2015;14:316-28.

171. Vanhauwaert S, Decaesteker B, De Brouwer S, Leonelli C, Durinck K, et al. In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors. Sci Rep 2018;8:17468.

172. Gonzalez-Nunez V, Noriega-Prieto JA, Rodriguez RE. Morphine modulates cell proliferation through mir133b &mir128 in the neuroblastoma SH-SY5Y cell line. Biochim Biophys Acta 2014;1842:566-72.

173. Afanasyeva EA, Hotz-Wagenblatt A, Glatting KH, Westermann F. New miRNAs cloned from neuroblastoma. BMC Genomics 2008;9:52.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: